Financial updates
Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026
Pharming Group N.V. presents its preliminary unaudited financial report for the three months ended March 31, 2026.
- First quarter 2026 total revenues were US$72.4 million, an 8% decrease compared to the first quarter 2025
- RUCONEST® revenue was US$58.4 million, a 15% decrease compared to the first quarter 2025, mainly due to anticipated inventory drawdowns and the planned exit from non-U.S. markets
- Joenja® revenue was US$14.1 million, a 34% increase compared to the first quarter of 2025, reflecting strong U.S. and international momentum
- Reaffirmed 2026 total revenue guidance of US$405 - US$425 million (8% - 13% growth)
- Generated positive net cash flow from operations of US$2.0 million in the quarter
- Joenja® approved in Japan and received positive CHMP opinion for APDS
- Resubmitted pediatric sNDA to the FDA for Joenja® (leniolisib) for highest doses; plan additional sNDA this summer for lowest doses
- Pharming to host a conference call today at 13:30 CEST (7:30 am EDT) (view webcast)